On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

This was the stock's fifth consecutive day of gains.